Highlights Protagonist Therapeutics, Inc.

Equities

PTGX

US74366E1029

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2025-07-10 EDT			5-day change	1st Jan Change
52.82 ^USD	+1.02%		+3.48%	+36.85%

07-07	Protagonist Therapeutics, Inc. - Special Call
06-17	Citigroup Initiates Protagonist Therapeutics at Buy With $72 Price Target	MT

Highlights

Protagonist Therapeutics, Inc. and Takeda Announce Asco Plenary Presentation Highlighting Full 32-Week Results from Phase 3 Verify Study of Rusfertide	06-02	CI
Protagonist Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	05-06	CI
Sector Update: Health Care Stocks Decline Late Afternoon	03-10	MT
Protagonist Therapeutics, Inc. Announces New Icotrokinra (Jnj-2113) Data from the Comprehensive Phase 3 Clinical Program and the Planned Initiation of the First-Ever Head-To-Head Study in Plaque Psoriasis	03-10	CI
Protagonist Therapeutics, Inc. and Takeda Pharmaceutical Company Limited Announces Positive Topline Results from Phase 3 Verify Study of Rusfertide in Patients with Polycythemia Vera	03-03	CI
Protagonist Therapeutics' Q4 Earnings, License and Collaboration Revenue Rise	02-21	MT
Earnings Flash (PTGX) Protagonist Therapeutics Posts Q4 License, Collaboration Revenue $170.6M	02-21	MT
Earnings Flash (PTGX) Protagonist Therapeutics Posts Q4 EPS $1.98	02-21	MT
Protagonist Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024	02-21	CI
Protagonist Reports Final Results From Rusfertide Phase 2 REVIVE Study Showing Durable Hematocrit Control at the ASH 2024 Annual Meeting	12-09	CI
Goldman Sachs Initiates Protagonist Therapeutics at Neutral With $47 Price Target	12-06	MT
Protagonist Therapeutics, Inc. Announces Positive Topline Results from Phase 3 ICONIC Studies of Icotrokinra (JNJ-2113)	11-18	CI
Protagonist Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	11-07	CI
Earnings Flash (PTGX) PROTAGONIST THERAPEUTICS Posts Q3 Revenue $4.7M	11-07	MT
Wedbush Initiates Protagonist Therapeutics at Outperform With $58 Price Target	11-05	MT
TD Cowen Initiates Protagonist Therapeutics at Buy	24-09-24	MT
Truist Initiates Protagonist Therapeutics at Buy With $60 Price Target	24-09-09	MT
Protagonist Therapeutics Shares Fall After Q2 Revenue Miss	24-08-06	MT
Protagonist Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	24-08-06	CI
Protagonist Therapeutics, Inc. Announces Publication of Phase 1 Clinical Data on JNJ-2113 in the Journal	24-08-01	CI
Protagonist Therapeutics to Join S&P SmallCap 600	24-06-28	MT
Protagonist Therapeutics, Inc. Reports Updated Long Term Results from Rusfertide Phase 2 REVIVE Study at the EHA2024 Congress Showowing Durable Hematocrit Control	24-06-14	CI
Protagonist Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	24-05-07	CI
Protagonist Therapeutics, Inc. Provides Update on Verify Patient Enrollment and Timing of Top-Line Data	24-03-26	CI
Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda	24-03-18	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Protagonist Therapeutics, Inc.

Equities

PTGX

US74366E1029

Biotechnology & Medical Research

Highlights

Filters